MarketResearchReports.Biz presents this most up-to-date research on "China Heparin Industry Report"
Albany, NY -- (SBWIRE) -- 10/11/2013 -- China Heparin Industry Report, 2013-2015
Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradually recognized internationally, China has grown into the largest heparin API producing and exporting country around the globe. Nevertheless, due to the stagnant demand in European and American markets in recent two years and the improved standards for heparin export, the export volume and value of heparin APIs in China both presented a decline trend during 2011-2012. In 2012, the export volume of heparin APIs in China only registered 103.86 tons (with a year-on-year decline of 1.3%), or about 14.5 trillion units (based on 140IU/mg), addressing 46.5% of global heparin API demand in corresponding period.
To Read The Complete Report with TOC: http://www.marketresearchreports.biz/analysis-details/china-heparin-industry-report-2013-2015
Hepalink, Nanjing King-friend, Dongcheng Biochemicals and Qianhong Bio-pharma are major suppliers of heparin API around the globe. With output and sales volume of heparin API above trillion units in recent years, the four enterprises have been the largest exporters of heparin in China for consecutive years, and shared over 70% of China’s total export of heparin.
Although leading heparin enterprises have had the plans of capacity expansion and heparin industrial chain improvement in previous years, affected by sluggish market demand, enhanced technical standards and other factors, a number of heparin API projects originally planned to start production in 2012 or 2013 were postponed successively, such as the 5T/A project of Hepalink, 2.8T/A project of Dongcheng Bio-chemicals, 4T/A unfractionated heparin sodium and 1.2T/A low-molecular-weight heparin sodium project of Nanjing King-friend. The API project of Qianhong Bio-pharma was completed at the end of 2012, but has not been put into production yet.
Nevertheless, from the perspective of projects proposed and under construction, it is predicted that the newly added capacity of heparin API in China will exceed 23 trillion units by 2015, and the total capacity in China will meet 80% of globe’s total demand.
Along with the increasing of heparin API deliverability, the competitiveness of heparin preparation products in China is also strengthened gradually. Taking the low-molecular-weight heparin calcium market as an example, the market share of GlaxoSmithKline’s Nadroparin in China was 61.0% in 2008, but the figure declined to 52.5% in 2011, and was estimated to decline to 40% or so in 2012. Nevertheless, the low-molecular-weight heparin calcium of Changshan Biochemical has become the first product in China that can compete with the overseas big brands. The revenue of the product only registered RMB86.93 million in 2011, and climbed up to RMB289.6 million in 2012.
China Heparin Industry Report, 2013-2015 mainly consists of the following contents:
- Entry barrier, global market supply & demand, competition pattern, forecast, etc. of heparin industry in China;
- Development status, market supply & demand, competition pattern, import & export, development prospect, etc. of heparin API industry in China;
- Development status, market supply & demand, competition pattern, development prospect, etc. of heparin preparation industry in China;
- Operation, heparin business, development prospect, etc. of seven heparin enterprises including Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Qianhong Bio-pharma and Changshan Biochemical.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/176520
TABLE OF CONTENT
1. Overview of Heparin Industry
1.1 Definition and Classification
1.2 Industrial Chain
2. Operating Environment of Heparin Industry in China
2.1 Entry Barrier
2.1.1 Related Policies
2.1.2 Technical Requirements
2.1.3 Capital Barrier
2.2 Global Market Supply & Demand
2.3 Global Market Competition
2.4 Global Market Forecast
3. Development of Heparin API Industry in China
3.1 Market Status
3.2 Market Supply & Demand
3.3 Competition Pattern
3.4 Import & Export
3.5 Development Prospect and Forecast
4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Low Molecular Heparin Preparation
4.2.1 Low Molecular Heparin Calcium Preparation
4.2.2 Low Molecular Heparin Sodium Preparation
4.3 Unfractionated Heparin Preparation
4.4 Development Prospect and Forecast
5. Key Heparin Enterprises in China
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D and Investment
5.1.6 Clients and Suppliers
5.1.7 Development Prospect
5.2 Qianhong Bio-pharma
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Clients and Suppliers
5.2.7 Heparin Business
5.2.8 Development Prospect
5.3 Dongcheng Biochemicals
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D and Investment
5.3.7 Heparin Business
5.3.8 Development Prospect
5.4 Changshan Biochemical
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D and Investment
5.4.6 Clients and Suppliers
5.4.7 Development Prospect
5.5 Tianjin Chase Sun
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D and Investment
5.5.6 Clients and Suppliers
5.5.7 Heparin Business
5.5.8 Development Prospect
5.6 Nanjing King-friend
5.6.2 Operation and Development Prospect
5.7 Jiangsu Wanbang
5.7.1 Wanbang Biochemical
5.7.2 Operation and Development Prospect
Global And China Display Driver IC Industry Report, 2013
The report includes the following aspects:
1. Display driver IC market
2. Flat panel display market
3. Ten display driver IC vendors
4. Eleven small and medium-sized display and driver IC vendors
The current decline in the ASP of driver IC is attributed to many factors, including:
- The display driver IC integration density continues to rise
- Driver IC is made by 12-inch fabs with the 90-nanometer process at high output efficiency
- Many vendors are willing to adopt RAM-Less driver IC in order to save costs.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/175854
In 2013, the display driver IC market will see the highest growth rate of 14.4% in the past five years and value USD7,111 million. The growth rate is expected to be 8.0% in 2014. The substantial growth is mainly boosted by mobile phones, whether smart phones or ordinary phones, whose screen resolution is soaring, which makes the high-end driver IC shipment surge.
Compared 1,040 models of mobile phones launched in 2012 with 759 models unveiled from January 1, 2013 to September 15, 2013, the share of FHD jumped the most quickly from 0.7% in 2012 to 17% in 2013. The ones with the pixel matrix of above 400ppi only accounted for 0.5% in 2012, but up to 12% in 2013. The proportion of the ones with over 300ppi ascended from 12% in 2012 to 28% in 2013.
Due to serious homogeneity, the competition among mobile phones is mainly reflected in screen, casing and camera pixel, especially screen. The formerly extraordinary screen looks inferior now. Even if the development of high-end smart phones slows down, the display is upgrading amazingly. Currently, LGD has developed a prototype of WQXGA (2560×1440) cell phone screen. Japan JDI also has the ability to develop WQXGA panels.
5.5-inch WQXGA corresponds to 534PPI, and 6-inch one to 489PPI. The mobile phones with WQXGA screen will be available at the end of 2013. Qualcomm and Mediatek have developed corresponding 8-thread MIPI interface which supports a transfer rate up to 9.6Gbps and a frame rate of 60Hz. In this case, 3D effects will be achieved without the help of any other device. In 2014, a number of flagship mobile phones will use WQXGA panels with the expected shipment of 130 million units.
China Sugar Industry Report, 2013-2015:http://www.marketresearchreports.biz/analysis/173657
From 2008/09 to 2013/14, the global supply of sugar has undergone changes from short supply to excess supply: raw sugar production increased from 140 million tons in 2008/09 to 170 million tons in 2012/13; while the demand for raw sugar was basically stabilized at about 150 million tons. It is expected that in 2013/14 global production of raw sugar may reach 174.9 million tons, with consumption to be 167.3 million tons, the global raw sugar industry continues to face destocking pressure.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/173657
As the world’s significant producing and importing country of sugar, China’s sugar output in 2012/13 climbed 13.5% YoY to 13.068 million tons, of which, Guangxi was the largest sugar producing area, with sugar production accounting for 63.7% of the total; followed by Yunnan (14.7%) and Guangdong (8.4%). In 2012, China imported 3.747 million tons of table sugar, hitting a record high.
Since 2012, despite the sustainable growth in downstream demand, sugar enterprises affected by falling prices of table sugar and rising production costs have witnessed increase of loss. From January to June 2013, among 296 domestic sugar enterprises above designated size, as many as 55.1% of them suffered losses, listed companies such as Guangxi Yangpu Nanhua Sugar Industry Group Co., Ltd. and Guangxi Guitang (Group) Co., Ltd. still faced destocking pressures, the sugar business would continue to face adverse conditions.
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948
FaceBook FanPage: https://www.facebook.com/marketresearchreports.biz